Astria Therapeutics, Inc. acquired by BioCryst for $13 per share, with the deal set to finalize in 1Q26. Click here to read why ATXS stock is a Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback